Because increased GSK-3 activity has been previously demonstrated to be linked to spatial learning deficits in AD transgenic mice [173,174], it may be speculated that activation of the AKT/GSK-3β pathway contributes, at least partly, to the improved cognitive abilities demonstrated following the M30 treatment, in APP/PS1 mice. Here, AKT1 is linked to Alzheimer disease.